MUC1 is a promising therapeutic target for prostate cancer therapy
about
Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancerDeletion of atbf1/zfhx3 in mouse prostate causes neoplastic lesions, likely by attenuation of membrane and secretory proteins and multiple signaling pathways.Prostate cancer invasion and metastasis: insights from mining genomic data.Current status of mucins in the diagnosis and therapy of cancer.The construction of chimeric T-Cell receptor with spacer base of modeling study of VHH and MUC1 interaction.Characterization of cancer associated mucin type O-glycans using the exchange sialylation properties of mammalian sialyltransferase ST3Gal-II.Race-associated biological differences among Luminal A breast tumors.Enhancement of DNA tumor vaccine efficacy by gene gun-mediated codelivery of threshold amounts of plasmid-encoded helper antigen.Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer.Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.The Tn antigen-structural simplicity and biological complexity.Label-free in vivo molecular imaging of underglycosylated mucin-1 expression in tumour cellsGeneration of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles.Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts.MUC1: The First Respiratory Mucin with an Anti-Inflammatory Function.5TR1 aptamer-PEGylated liposomal doxorubicin enhances cellular uptake and suppresses tumour growth by targeting MUC1 on the surface of cancer cells.
P2860
Q28235980-A047FDD1-6746-413F-9E4D-50BCE815F9CDQ30410016-44D9652B-0781-4F92-B8A5-36CD1A2DB356Q30656758-9E22ABD1-1E25-4519-A9FD-5B48BA674D25Q33757326-08C29D1F-D15B-41B1-9C94-3FE86B50AD35Q35176505-A8FE6EBA-C742-4133-8D38-F9F5D967DA49Q35874802-607EB170-DF5D-4292-BEBE-F6FD507B901CQ35922859-3A32A80A-D9A4-42F2-BD4C-AAA432CC5D84Q37039140-1DAFEA23-9642-4176-A77A-C300DCC0D507Q37408608-9E388C60-B381-4523-BBAB-E888099B37A5Q37443603-94877A0B-9F08-4274-92D8-BC9AB38286E5Q37831859-76008789-6684-4B96-A6AA-7601C5ADEF8FQ38894517-6C9B6807-B2B1-403E-910E-B1F49D090CD1Q41903428-AA6D2E6D-CA6D-46CA-9516-90F4B609C5BEQ42760416-052D97A7-F337-4877-8105-96D565C730F0Q47696532-93D18407-7211-4EA9-9ACE-F5D357088C7EQ48581486-5A14CA15-FBA7-46F1-9850-6BF80A80E728
P2860
MUC1 is a promising therapeutic target for prostate cancer therapy
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
MUC1 is a promising therapeutic target for prostate cancer therapy
@ast
MUC1 is a promising therapeutic target for prostate cancer therapy
@en
MUC1 is a promising therapeutic target for prostate cancer therapy
@nl
type
label
MUC1 is a promising therapeutic target for prostate cancer therapy
@ast
MUC1 is a promising therapeutic target for prostate cancer therapy
@en
MUC1 is a promising therapeutic target for prostate cancer therapy
@nl
prefLabel
MUC1 is a promising therapeutic target for prostate cancer therapy
@ast
MUC1 is a promising therapeutic target for prostate cancer therapy
@en
MUC1 is a promising therapeutic target for prostate cancer therapy
@nl
P1476
MUC1 is a promising therapeutic target for prostate cancer therapy
@en
P304
P356
10.2174/156800907780618338
P407
P577
2007-05-01T00:00:00Z